ClinicalTrials.gg
CompletedNCT01513460Updated Jan 5, 2015Results posted

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of NVA237 50µg once daily and Tiotropium 18µg once daily in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 68 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
773
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
16th of 73
773 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
20th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 16th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 20th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease,
  • NVA 237,
  • glycopyrronium,
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Moderate to Severe (Stage II or Stage III) according to the GOLD 2010 guideline
  • Current or ex-smokers who have a smoking history of at least 10 pack years
  • Qualifying at Visit 2 (day -7)

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of asthma or a history of high blood eosinophil count (>600/mm³)
  • Patients with concomitant pulmonary disease
  • Patients with lung lobectomy or lung volume reduction or lung transplantation
  • Patients with α-1 antitrypsin deficiency
  • Patients who have had within 30 days prior to screening visit or during run-in period

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
773 participants (actual)

Study arms

  • Experimental
    NVA237 + Fluticasone/Salmeterol (Flu/Sal)

    NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.

    Drug: NVA237 50µg once daily · Drug: Flu/Sal · Drug: NVA237 placebo + Tiotropium placebo.

  • Active comparator
    Tiotropium + Flu/Sal

    Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.

    Drug: Tiotropium 18µg once daily · Drug: Flu/Sal · Drug: NVA237 placebo + Tiotropium placebo.

  • Placebo comparator
    Flu/Sal

    Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.

    Drug: Flu/Sal · Drug: NVA237 placebo + Tiotropium placebo.

Interventions

  • NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)

  • Tiotropium 18 μg o.d. delivered via a proprietary inhalation device

  • DrugFlu/Sal

    Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device

  • DrugNVA237 placebo + Tiotropium placebo.

    Tiotropium 18 μg o.d. delivered via a proprietary inhalation device

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium)

    Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15 hours and 23:45 hours after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45 min and 15 min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.

    Time frame: baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline in Mean Trough FEV1 (Flu/Sal Versus NVA237/Tiotropium+Flu/Sal)

    Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks

  2. Change From Baseline in Mean Trough FEV1

    Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks

  3. Change From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment

    SGRQ-C is a health related quality of life questionnaire consisting of 40 items divided into two components: 1) symptoms, 2) activity\& impacts. The lowest possible value is zero and the highest is 100. Higher values corresponded to greater impairment in quality of life. An analysis model included terms for treatment, baseline total SGRQ score, FEV1 and baseline smoking status. The model also contained as fixed effects the baseline total SGRQ score, FEV1 prior to inhalation of short acting bronchodilator, FEV1 post inhalation of short acting bronchodilator and stratification factors as covariates. A negative change from baseline indicates improvement.

    Time frame: 12 weeks

  4. Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use

    The total number of puffs of rescue medication used over the last 12 h recorded in the morning (nighttime use) and in the evening (daytime use) over the full 12 weeks was divided by the total number of days with non-missing rescue data to derive the mean daytime and nighttime number of puffs of rescue medication. Change from baseline in the mean daytime and nighttime number of puffs of rescue medication was analyzed as for the change from baseline in the mean daily number of puffs of rescue medication.

    Time frame: baseline, 12 weeks

  5. Mean Percentage of Nights With 'no Nighttime Awakenings'

    A night with 'no nighttime awakenings' is defined from diary data as any night where patient did not wake up due to symptoms. Total number of nights with 'no nighttime awakenings' over treatment period was divided by total number of nights where diary recordings have been made in order to derive percentage of 'no nighttime awakenings' which will be summarized by treatment and analyzed using a similar mixed model as specified for primary analysis. Diary data recorded during the 7 day run-in period was used to calculate baseline percentage of nights 'no nighttime awakenings'.

    Time frame: 12 weeks

  6. Mean Percentage of Days With Performance of Usual Activities

    A 'day able to perform usual daily activities' was defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The percentage of 'days able to perform usual daily activities' was derived and analyzed using a similar mixed model as specified for primary analysis as for the percentage of nights with 'no nighttime awakenings'.

    Time frame: 12 weeks

07

Results

Posted Jan 5, 2015

Participant flow

Participant flow — Overall Study
MilestoneNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Started258258257
Full analysis set257258257
Per-protocol set196186166
Completed229226201
Not completed293256
Withdrew: Death001
Withdrew: Lost to follow-up002
Withdrew: Abnormal laboratory value101
Withdrew: Lack of efficacy125
Withdrew: Protocol deviations343
Withdrew: Withdrawal by subject7821
Withdrew: Adverse event161823
Withdrew: Abnormal test procedure100

Outcome measures

PrimaryChange From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium)

Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15 hours and 23:45 hours after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45 min and 15 min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.

Time frame:
baseline, 12 weeks
Reported as:
Mean · liters
Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium)
litersNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/Sal
Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium)0.095 ± 0.01310.102 ± 0.0135
SecondaryChange From Baseline in Mean Trough FEV1 (Flu/Sal Versus NVA237/Tiotropium+Flu/Sal)

Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.

Time frame:
baseline, 4 weeks, 8 weeks, 12 weeks
Reported as:
Mean · Liters
Change From Baseline in Mean Trough FEV1 (Flu/Sal Versus NVA237/Tiotropium+Flu/Sal)
LitersFlu/SalNVA237/Tiotropium+Flu/Sal
Week 4-0.010 ± 0.00990.077 ± 0.0073
Week 8-0.002 ± 0.00990.088 ± 0.0073
Week 12-0.012 ± 0.00990.088 ± 0.0073
SecondaryChange From Baseline in Mean Trough FEV1

Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.

Time frame:
baseline, 4 weeks, 8 weeks, 12 weeks
Reported as:
Mean · Liters
Change From Baseline in Mean Trough FEV1
LitersNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Week 40.077 ± 0.01000.077 ± 0.0101-0.010 ± 0.0099
Week 80.084 ± 0.01000.092 ± 0.0101-0.002 ± 0.0099
Week 120.089 ± 0.01000.087 ± 0.0101-0.012 ± 0.0099
SecondaryChange From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment

SGRQ-C is a health related quality of life questionnaire consisting of 40 items divided into two components: 1) symptoms, 2) activity\& impacts. The lowest possible value is zero and the highest is 100. Higher values corresponded to greater impairment in quality of life. An analysis model included terms for treatment, baseline total SGRQ score, FEV1 and baseline smoking status. The model also contained as fixed effects the baseline total SGRQ score, FEV1 prior to inhalation of short acting bronchodilator, FEV1 post inhalation of short acting bronchodilator and stratification factors as covariates. A negative change from baseline indicates improvement.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment
units on a scaleNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Change From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment-2.806 ± 0.6772-3.902 ± 0.6920-0.652 ± 0.6871
SecondaryChange From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use

The total number of puffs of rescue medication used over the last 12 h recorded in the morning (nighttime use) and in the evening (daytime use) over the full 12 weeks was divided by the total number of days with non-missing rescue data to derive the mean daytime and nighttime number of puffs of rescue medication. Change from baseline in the mean daytime and nighttime number of puffs of rescue medication was analyzed as for the change from baseline in the mean daily number of puffs of rescue medication.

Time frame:
baseline, 12 weeks
Reported as:
Mean · puffs of rescue medication
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use
puffs of rescue medicationNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use2.191 ± 0.13842.093 ± 0.13972.908 ± 0.1395
SecondaryMean Percentage of Nights With 'no Nighttime Awakenings'

A night with 'no nighttime awakenings' is defined from diary data as any night where patient did not wake up due to symptoms. Total number of nights with 'no nighttime awakenings' over treatment period was divided by total number of nights where diary recordings have been made in order to derive percentage of 'no nighttime awakenings' which will be summarized by treatment and analyzed using a similar mixed model as specified for primary analysis. Diary data recorded during the 7 day run-in period was used to calculate baseline percentage of nights 'no nighttime awakenings'.

Time frame:
12 weeks
Reported as:
Mean · Percentage of nights
Mean Percentage of Nights With 'no Nighttime Awakenings'
Percentage of nightsNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Mean Percentage of Nights With 'no Nighttime Awakenings'0.834 ± 0.01240.816 ± 0.01240.823 ± 0.0124
SecondaryMean Percentage of Days With Performance of Usual Activities

A 'day able to perform usual daily activities' was defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The percentage of 'days able to perform usual daily activities' was derived and analyzed using a similar mixed model as specified for primary analysis as for the percentage of nights with 'no nighttime awakenings'.

Time frame:
12 weeks
Reported as:
Mean · Percentage of days
Mean Percentage of Days With Performance of Usual Activities
Percentage of daysNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Mean Percentage of Days With Performance of Usual Activities0.934 ± 0.00870.946 ± 0.00880.903 ± 0.0088

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 + Fluticasone/Salmeterol (Flu/Sal)—15/257 (5.8%)114/257 (44.4%)
Tiotropium + Flu/Sal—22/258 (8.5%)124/258 (48.1%)
Flu/Sal—15/257 (5.8%)111/257 (43.2%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Small intestinal obstructionGastrointestinal disorders2/2570/2580/257
PneumoniaInfections and infestations0/2572/2582/257
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2571/2582/257
Atrial fibrillationCardiac disorders0/2572/2581/257
AnaemiaBlood and lymphatic system disorders0/2570/2581/257
Acute coronary syndromeCardiac disorders0/2571/2581/257
Angina pectorisCardiac disorders0/2571/2581/257
Atrial flutterCardiac disorders1/2571/2580/257
Ventricular fibrillationCardiac disorders0/2570/2581/257
VertigoEar and labyrinth disorders1/2570/2580/257
Most frequent other events
Showing 10 of 46
Most frequent other events
EventNVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/Sal
Upper respiratory tract infectionInfections and infestations17/25713/25811/257
CoughRespiratory, thoracic and mediastinal disorders16/25715/25811/257
DysphoniaRespiratory, thoracic and mediastinal disorders6/25715/2585/257
HeadacheNervous system disorders3/2574/25813/257
Oral candidiasisInfections and infestations12/25713/2589/257
Muscle spasmsMusculoskeletal and connective tissue disorders11/2579/2585/257
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/25710/2588/257
DyspnoeaRespiratory, thoracic and mediastinal disorders7/2578/2589/257
Dry mouthGastrointestinal disorders5/2579/2582/257
NauseaGastrointestinal disorders3/2579/2583/257

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/SalTotal
Mean68.2 ± 8.3868.0 ± 7.7467.8 ± 8.4968.0 ± 8.20
Sex: Female, Male
Sex: Female, Male(Participants)NVA237 + Fluticasone/Salmeterol (Flu/Sal)Tiotropium + Flu/SalFlu/SalTotal
Female949883275
Male163160174497
08

Study locations

68 sites
  • Novartis Investigative Site
    Baulkham Hills, New South Wales 2153, Australia
  • Novartis Investigative Site
    Brookvale, New South Wales 2100, Australia
  • Novartis Investigative Site
    Castle Hill, New South Wales 2067, Australia
  • Novartis Investigative Site
    Dapto, New South Wales, Australia
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Ermington, New South Wales, Australia
  • Novartis Investigative Site
    Gosford, New South Wales 2250, Australia
  • Novartis Investigative Site
    Hinchinbrook, New South Wales 2168, Australia
  • Novartis Investigative Site
    Kingswood, New South Wales 2747, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2089, Australia
  • Novartis Investigative Site
    Arundel, Queensland 4214, Australia
  • Novartis Investigative Site
    Aspley, Queensland 4034, Australia
  • Novartis Investigative Site
    Beenleigh, Queensland 4207, Australia
  • Novartis Investigative Site
    Browns Plains, Queensland 4118, Australia
  • Novartis Investigative Site
    Chemside, Queensland 4032, Australia
  • Novartis Investigative Site
    Deception Bay, Queensland 4508, Australia
  • Novartis Investigative Site
    Everton Plaza, Queensland 4053, Australia
  • Novartis Investigative Site
    Holland Park, Queensland 4121, Australia
  • Novartis Investigative Site
    Jimboomba, Queensland 4032, Australia
  • Novartis Investigative Site
    Kedron, Queensland, Australia
  • Novartis Investigative Site
    Kenmore, Queensland 4069, Australia
  • Novartis Investigative Site
    Kippa Ring, Queensland 4021, Australia
  • Novartis Investigative Site
    Logan Central, Queensland 4114, Australia
  • Novartis Investigative Site
    Loganholme, Queensland 4129, Australia
  • Novartis Investigative Site
    Mermaid Beach, Queensland 4218, Australia
  • Novartis Investigative Site
    Morayfield, Queensland 4506, Australia
  • Novartis Investigative Site
    Nerang, Queensland 4211, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Daw Park, South Australia 5041, Australia
  • Novartis Investigative Site
    Glenelg East, South Australia 5045, Australia
  • Novartis Investigative Site
    Golden Grove, South Australia 5125, Australia
  • Novartis Investigative Site
    Hamley Bridge, South Australia 5401, Australia
  • Novartis Investigative Site
    Kensington Gardens, South Australia 5065, Australia
  • Novartis Investigative Site
    Prospect, South Australia 5082, Australia
  • Novartis Investigative Site
    Dandenong, Victoria, Australia
  • Novartis Investigative Site
    Lalor, Victoria 3075, Australia
  • Novartis Investigative Site
    Malvern, Victoria 3144, Australia
  • Novartis Investigative Site
    Melbourne, Victoria, Australia
  • Novartis Investigative Site
    Noble Park, Victoria 3174, Australia
  • Novartis Investigative Site
    Oakleigh East, Victoria 3166, Australia
  • Novartis Investigative Site
    Preston, Victoria, Australia
  • Novartis Investigative Site
    Rosebud, Victoria 3063, Australia
  • Novartis Investigative Site
    Bicton, Western Australia, Australia
  • Novartis Investigative Site
    East Fremantle, Western Australia 6158, Australia
  • Novartis Investigative Site
    East Victoria Park, Western Australia 6101, Australia
  • Novartis Investigative Site
    Fremantle, Western Australia 6160, Australia
  • Novartis Investigative Site
    Mirrabooka, Western Australia 6061, Australia
  • Novartis Investigative Site
    Morley, Western Australia 6062, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Noranda, Western Australia, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6000, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6069, Australia
  • Novartis Investigative Site
    Perth, Western Australia, Australia
  • Novartis Investigative Site
    Pinjarra, Western Australia, Australia
  • Novartis Investigative Site
    Spearwood, Western Australia 6163, Australia
  • Novartis Investigative Site
    Woodvale, Western Australia 6026, Australia
  • Novartis Investigative Site
    Yokine, Western Australia 6060, Australia
  • Novartis Investigative Site
    Auckland, 1051, New Zealand
  • Novartis Investigative Site
    Auckland, New Zealand
  • Novartis Investigative Site
    Christchurch, New Zealand
  • Novartis Investigative Site
    Dunedin, New Zealand
  • Novartis Investigative Site
    Grafton, Auckland, 1010, New Zealand
  • Novartis Investigative Site
    Hamilton, 3240, New Zealand
  • Novartis Investigative Site
    Tauranga, 3143, New Zealand
  • Novartis Investigative Site
    Tauranga, New Zealand
  • Novartis Investigative Site
    Wellington, 6021, New Zealand
  • Novartis Investigative Site
    Wellington, New Zealand
09

References and documents

Publications

  • Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N; Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015 Jun;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670. Epub 2015 Apr 3. PubMed 25841237 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 20, 2012
Start
Apr 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Jan 5, 2015
Last update
Jan 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01513460
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Apr 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Jan 5, 2015
Last update
Jan 5, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion